Trial · NCT03382600
Adverse events252
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 252
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 13 | 54 | |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 18 | 46 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 4 | 54 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1 | 46 | |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 | 54 | |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 6 | 46 | |
| other | Vertigo | Ear and labyrinth disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 | 54 | |
| other | Vertigo | Ear and labyrinth disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 0 | 46 | |
| other | Adrenal insufficiency | Endocrine disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 | 54 | |
| other | Adrenal insufficiency | Endocrine disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 | 46 | |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 5 | 54 | |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 | 46 | |
| other | Cataract | Eye disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 0 | 54 | |
| other | Cataract | Eye disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 | 46 | |
| other | Lacrimation increased | Eye disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 5 | 54 | |
| other | Lacrimation increased | Eye disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 2 | 46 | |
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 | 54 | |
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 | 46 | |
| other | Cheilitis | Gastrointestinal disorders | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 0 | 54 | |
| other | Cheilitis | Gastrointestinal disorders | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 4 | 46 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03382600/events